On this page
Tufting enteropathy
This condition is characterised by abnormal development of the intestinal lining, impairing nutrient absorption. It typically presents shortly after birth, causing significant health challenges that often require specialised medical care and nutritional support.
Available at Jeen Health
Clinical tests that include this
Overview
Tufting enteropathy is a rare genetic disorder that impacts the normal structure and function of the small intestine. It is one of several conditions classified as congenital diarrhoeal disorders. The condition is characterised by specific changes in the intestinal lining, including the formation of 'tufts' of cells and a reduction in the normal folds (villi) that absorb nutrients [PMID:24075421]. These structural abnormalities severely compromise the intestine's ability to absorb water and nutrients from food, leading to persistent, watery diarrhoea from a very early age, often within the first days or weeks of life.
Because of the severe malabsorption, infants with tufting enteropathy often struggle to gain weight and grow properly. The condition requires careful medical management, typically involving specialised nutritional support, often delivered intravenously (parenteral nutrition), to ensure adequate growth and development.
Symptoms & clinical features
The hallmark symptom of tufting enteropathy is severe, watery diarrhoea that begins very early in life, often shortly after birth. This persistent diarrhoea can lead to significant dehydration and electrolyte imbalances, which are critical concerns for newborns and infants. Affected infants typically experience poor weight gain and growth, a condition known as 'failure to thrive', due to the intestine's inability to absorb necessary nutrients.
Other symptoms can include abdominal distension and, in some cases, symptoms related to dehydration, such as reduced urination and lethargy. The severity of symptoms can vary, but generally, the condition presents with significant gastrointestinal distress. Early recognition of these symptoms is crucial for timely diagnosis and management.
Video: Genetics 101
Affected organs
The primary organ affected in tufting enteropathy is the small intestine. The microscopic structure of the small intestine is critical for nutrient absorption, and in this condition, these structures are significantly altered. The normal finger-like projections (villi) that line the intestine, which are responsible for absorbing nutrients, are often blunted or absent. Additionally, characteristic 'tufts' or clusters of epithelial cells can be seen on the surface of the intestinal lining during microscopic examination [PMID:24075421]. These changes severely impair the absorptive capacity of the gut, leading to the clinical features of the condition.
Risks & severity
Tufting enteropathy is a severe condition that presents significant health risks, particularly in infancy. The chronic, severe diarrhoea and malabsorption can lead to severe dehydration, electrolyte imbalances, and significant malnutrition if not managed effectively. Without appropriate nutritional support, affected infants are at risk for complications related to poor growth and development.
The severity of the condition means that affected individuals often require long-term, intensive medical care. Historically, outcomes were very poor, but advances in parenteral nutrition and medical management have improved the prognosis for many individuals. However, it remains a life-threatening condition, and continued research aims to improve understanding and treatment options.
Genetic causes
Tufting enteropathy is primarily caused by genetic changes (variants) in two main genes: EPCAM and SPINT2. The EPCAM gene provides instructions for making a protein called epithelial cell adhesion molecule, which plays a vital role in cell-to-cell communication and adhesion within epithelial tissues, such as the lining of the intestine [PMID:21350819]. Pathogenic variants in EPCAM disrupt these normal cellular functions, leading to the abnormal development of the intestinal lining characteristic of tufting enteropathy.
The SPINT2 gene provides instructions for making a protein called serine peptidase inhibitor, Kunitz type 2. This protein is involved in regulating cell growth and differentiation. Pathogenic variants in SPINT2 can also lead to the intestinal abnormalities seen in tufting enteropathy, although they may sometimes present with slightly different clinical features. Both genes are crucial for the proper development and function of the intestinal epithelium.
- EPCAM epithelial cell adhesion moleculeThe EPCAM gene provides instructions for the epithelial cell adhesion molecule, a protein essential for cell-to-cell adhesion and critical signalling pathways involved in cell growth, division, and differentiation.
- SPINT2 serine peptidase inhibitor, Kunitz type 2
Inheritance pattern
Tufting enteropathy follows an autosomal recessive pattern of inheritance. This means that an individual must inherit two copies of a pathogenic variant - one from each parent - to develop the condition. If a person inherits only one copy of a pathogenic variant, they are considered a 'carrier' and typically do not show symptoms of the condition themselves. Carriers can, however, pass on the pathogenic variant to their children.
If both parents are carriers of a pathogenic variant in the same gene (either EPCAM or SPINT2), there is a 25% (1 in 4) chance with each pregnancy that their child will inherit two copies of the pathogenic variant and develop tufting enteropathy. There is also a 50% (1 in 2) chance that their child will be a carrier, and a 25% chance that their child will inherit two unaffected copies of the gene.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of tufting enteropathy is typically suspected in infants presenting with severe, persistent watery diarrhoea from birth, accompanied by poor weight gain. The definitive diagnosis relies on specific findings from an intestinal biopsy. During this procedure, a small tissue sample is taken from the small intestine and examined under a microscope. Characteristic features, such as the presence of 'tufts' of epithelial cells and abnormalities in the villi, confirm the diagnosis.
Once clinical and histological features suggest tufting enteropathy, genetic testing is used to identify the specific pathogenic variants in the EPCAM or SPINT2 genes. This molecular diagnosis is crucial for confirming the condition, aiding in genetic counselling for the family, and potentially guiding prognosis. In the UK, genetic testing for congenital diarrhoeal disorders may be accessed via the NHS Genomic Medicine Service, often following referral to a clinical genetics service or specialist paediatric gastroenterology team (NHS R-code: R416).
Management & lifestyle
Management of tufting enteropathy is complex and primarily focuses on providing adequate nutrition and hydration. Due to the severe malabsorption, most affected infants require parenteral nutrition, where nutrients are delivered directly into the bloodstream, bypassing the digestive system. This is a critical life-sustaining treatment that helps ensure proper growth and development. Enteral feeding (tube feeding) may be considered in some cases, often in combination with parenteral nutrition, depending on the individual's tolerance and intestinal function.
Ongoing care involves careful monitoring of hydration, electrolyte balance, and nutritional status by a multidisciplinary team including paediatric gastroenterologists, dietitians, and specialist nurses. Some individuals may eventually be able to tolerate some oral feeds or transition to exclusive enteral nutrition. Research continues into potential long-term management strategies and improving quality of life for affected individuals. Families should seek advice from their clinical team regarding specific care plans and available support.
UK care pathway
In the UK, individuals suspected of having tufting enteropathy would typically be referred to specialist paediatric gastroenterology services. Following clinical assessment and initial diagnostic tests, a referral to a clinical genetics service may be made. Genetic testing for congenital diarrhoeal disorders, including tufting enteropathy, is available through the NHS Genomic Medicine Service, often via specific R-codes such as R416 (Congenital diarrhoeal disorders). A genetic counsellor can provide essential information about the inheritance pattern, implications for other family members, and support options.
Frequently asked questions
What is the typical age when tufting enteropathy symptoms first appear?
Symptoms of tufting enteropathy typically begin very early in life, often within the first few days or weeks after birth. The most prominent symptom is severe, watery diarrhoea.
Is tufting enteropathy a common condition?
No, tufting enteropathy is considered a rare condition. Exact prevalence figures are not well established, but it affects a very small number of infants worldwide.
Can siblings be affected by tufting enteropathy?
Yes, because tufting enteropathy is inherited in an autosomal recessive manner, if parents are carriers, there is a 25% chance with each pregnancy for a sibling to be affected. Genetic counselling can provide specific risk information for families.
What kind of medical team manages tufting enteropathy?
Management of tufting enteropathy typically involves a multidisciplinary team, including paediatric gastroenterologists, dietitians, specialist nurses, and sometimes clinical geneticists, to provide comprehensive care and nutritional support.
Are there any treatments for tufting enteropathy?
Currently, there is no cure for tufting enteropathy. Management focuses on supportive care, primarily through specialised nutrition, often parenteral nutrition (IV feeding), to ensure adequate hydration and nutrient intake for growth and development.
References
- Das B, Sivagnanam M. Congenital Tufting Enteropathy: Biology, Pathogenesis and Mechanisms. Journal of clinical medicine. 2020. PMID: 33374714
- Cai C, Chen Y, Chen X. Tufting Enteropathy: A Review of Clinical and Histological Presentation, Etiology, Management, and Outcome. Gastroenterology research and practice. 2020. PMID: 33029133
- Goulet O, Salomon J, Ruemmele F. Intestinal epithelial dysplasia (tufting enteropathy). Orphanet journal of rare diseases. 2007. PMID: 17448233
- Sawczenko A, Sandhu BK. Newer diarrheal syndromes. Indian journal of pediatrics. 1999. PMID: 11132469
- Güvenoğlu M, Şimşek-Kiper PÖ, Koşukcu C. Homozygous Missense Epithelial Cell Adhesion Molecule Variant in a Patient with Congenital Tufting Enteropathy and Literature Review. Pediatric gastroenterology, hepatology & nutrition. 2022. PMID: 36451688
- Fang Y, Luo Y, Xu L. Case Series of Eight Congenital Tufting Enteropathy Patients and Literature Review. Clinical genetics. 2025. PMID: 39980129
- Noyan A, Gümüş E, Hızarcıoğlu Gülşen H. Three cases of tufting enteropathy and review of literature. The Turkish journal of pediatrics. 2026. PMID: 42172468
- Montoya-Cerrillo D, Bernieh A, Saad AG. Critical diagnoses in paediatric gastrointestinal diseases. Pathology. 2022. PMID: 35033374